TD Cowen reaffirmed a “Buy” rating on AutoZone, Inc. (NYSE:AZO) with a price target of $4,300. TD Cowen analyst, Max Rakhlenko, emphasized that the company is performing well despite some short-term ...

We recently published a list of Jim Cramer’s Game Plan: 12 Stocks in Focus. In this article, we are going to take a look at ...

AutoZone remains a top long-term holding, compounding value through consistent growth, international expansion, and an ...

This revision follows the company’s FQ3 2025 report, which saw AutoZone deliver a domestic comparable sales beat but ...

Comparable sales were up 3.2% during the quarter to beat the consensus estimate for a rise of 1.8%. Domestic comparable sales ...

Chief Financial Officer Jackson reported inflation was "roughly flat" year-over-year, with about 1% this quarter. Forward ...

UTIs are among the most common infections worldwide, affecting some 15 million women a year. Phenazopyridine, sold under brand names such as Azo and Uristat, is used to treat the pain, burning and ...

Fintel reports that on May 21, 2025, B of A Securities upgraded their outlook for AutoZone (NYSE:AZO) from Neutral to Buy.

Q3 2025 Earnings Call Transcript May 27, 2025 AutoZone, Inc. misses on earnings expectations. Reported EPS is $35.36 EPS, expectations were $37.11. Operator: Greetings. Welcome to AutoZone’s 2025 Q3 ...

AutoZone missed Q3 earnings estimates on weaker margins despite solid sales growth, but remains optimistic heading into the ...

A widely available drug for urinary tract infections has never been formally approved by the US government. It’s not the only ...

AutoZone Inc on Tuesday reported a 6.6% drop in quarterly profit, as softening demand and currency fluctuations weighed on ...